

# Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis

GIOVANNI FILOCAMO, ALESSANDRO CONSOLARO, BENEDETTA SCHIAPPAPIETRA, NICOLINO RUPERTO, ANGELA PISTORIO, NICOLETTA SOLARI, SILVIA PEDERZOLI, SARA VERAZZA, ALBERTO MARTINI, and ANGELO RAVELLI

**ABSTRACT. Objective.** To explore the parent and child acceptable symptom state in juvenile arthritis (JA-PASS and JA-CASS, respectively) and estimate the JA-PASS and JA-CASS cutoff values for outcome measures.

**Methods.** Children with juvenile idiopathic arthritis (JIA) and their parents completed a multi-dimensional questionnaire that included parent-reported and child-reported outcomes and a question about whether they considered the disease state as satisfactory. Additional assessments included demographic data, physician-reported outcomes, and acute-phase reactant levels. Stepwise logistic regression was used to assess contributors to JA-PASS and JA-CASS. Cutoff values of outcome measures that defined JA-PASS and JA-CASS were determined using both 75th percentile and receiver-operating characteristic (ROC) curve methods. Testing procedures included evaluation of discriminative and construct validity of the satisfaction question and assessment of reliability of JA-PASS and JA-CASS cutoffs.

**Results.** Of 584 parents, 385 (65.9%) considered their child in JA-PASS. Of 343 children, 236 (68.8%) considered themselves in JA-CASS. Significant contributors to being in either JA-PASS or JA-CASS were absence of active joints, better rating of overall well-being, and better physical function or health. Cutoff values yielded by 75th percentile and ROC curve methods were similar. Parent, child, and physician global ratings yielded the lowest percentage of false-positive misclassification and the best tradeoff between sensitivity and specificity. The satisfaction question showed good discriminative and construct validity and the JA-PASS and JA-CASS cutoffs were found to be stable over time.

**Conclusion.** The acceptable symptom state is a relevant concept for children with JIA and their parents and constitutes a valid outcome measure that is potentially applicable in routine practice and clinical trials. (J Rheumatol First Release Feb 1 2012; doi:10.3899/jrheum.110745)

## Key Indexing Terms:

JUVENILE IDIOPATHIC ARTHRITIS  
HEALTH STATUS

PEDIATRIC RHEUMATOLOGY  
ACCEPTABLE SYMPTOM STATE

Over the last 20 years, there have been major advances in the treatment of juvenile idiopathic arthritis (JIA), which include the widespread use of methotrexate and intraarticular corticosteroids, the earlier introduction of these drugs,

and more recently, the availability of the new biologic agents<sup>1,2,3,4,5</sup>. At the same time, the number of controlled clinical trials in JIA has grown sharply<sup>6</sup>. These advances have increased the potential to achieve disease remission or at least to lower levels of disease activity, and have consequently shifted therapeutic aims increasingly toward the attainment of inactive disease<sup>6,7,8,9</sup>. This has led to the notion that in JIA clinical trials it is important not only to know the magnitude of clinical improvement from baseline, but also to understand whether the observed change leads to an acceptable state according to the physician, the parent, or the child<sup>10,11,12,13</sup>.

In recent years there has been a great deal of effort to develop measures of disease activity in JIA, leading to the generation of definitions for clinical remission (CR)<sup>7</sup> and minimal disease activity (MDA)<sup>12</sup>. However, CR criteria are based only on physician-reported outcomes and acute-phase reactant levels, while parent proxy-reported and child self-reported outcomes are neglected<sup>9</sup>. Although the parent global assessment is part of the MDA criteria for polyarthritis, no

---

From the Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Genoa; the Policlinico S. Orsola-Malpighi, Bologna; and the Università degli Studi di Genova, Genoa, Italy.

G. Filocamo, MD, PhD, Dirigente medico, Policlinico S. Orsola-Malpighi, IRCCS G. Gaslini; A. Consolaro, MD, Research Fellow, IRCCS G. Gaslini, Università degli Studi di Genova; B. Schiappapietra, MD, Resident in Pediatrics; N. Ruperto, MD, MPH, Dirigente medico; A. Pistorio, MD, PhD, Dirigente medico, IRCCS G. Gaslini; N. Solari, MD, Research Fellow, IRCCS G. Gaslini, Università degli Studi di Genova; S. Pederzoli, MD, Research Fellow; S. Verazza, MD, Resident in Pediatrics, IRCCS G. Gaslini; A. Martini, MD, Professor of Pediatrics; A. Ravelli, MD, Associate Professor of Pediatrics, IRCCS G. Gaslini, Università degli Studi di Genova.

Drs. Filocamo and Consolaro contributed equally to this work.

Address correspondence to Dr. A. Ravelli, Pediatria II, Istituto G. Gaslini, Largo G. Gaslini 5, 16147 Genoa, Italy.

E-mail: angeloravelli@ospedale-gaslini.ge.it

Accepted for publication November 3, 2011.

---

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2012. All rights reserved.

parent/child-reported measures are included in the MDA definition for oligoarthritis. Hence, definitions of both CR and MDA may not adequately reflect the parent's and/or the child's perception of the disease status. Physicians, parents, and children often disagree in assessing different aspects of disease activity, including remission, in JIA<sup>14,15,16,17</sup>.

In adult rheumatology, the need to know whether the observed change in a clinical trial leads to an acceptable state according to the patient has led to the concept of patient acceptable symptom state (PASS)<sup>11,18,19,20,21</sup>. The PASS has been defined as the symptom threshold beyond which patients consider their health status as satisfactory. It has been suggested that the PASS constitutes an ambitious target for disease management<sup>18</sup>.

At present, the definition of an acceptable symptom state does not exist for JIA. Therefore, the primary aim of our study was to identify the cutoff values of outcome measures that define the symptom state considered acceptable by children with JIA and their parents. A secondary aim was to examine the validity of the cutoffs and the acceptable symptom state concept.

## MATERIALS AND METHODS

**Patient selection.** The study sample was composed of consecutive patients seen between March 2007 and December 2009 who were  $\leq 18$  years old and were diagnosed with JIA by the International League of Associations for Rheumatology (ILAR) criteria<sup>21</sup>. All parents/guardians provided written informed consent for participation in the study. The study was approved by the institutional review board of the Istituto G. Gaslini, Genoa, Italy.

**Assessment of parent/child-reported outcomes.** A parent (the mother, whenever possible) or legal guardian of each patient was asked to complete the Italian parent version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)<sup>22</sup>. The child (if aged more than 7–8 years) was also asked to complete independently the Italian patient version of the JAMAR<sup>22</sup>. A researcher assisted parents and children if they had questions during questionnaire completion. However, no questionnaire was administered in the form of an interview. The JAMAR is a multidimensional questionnaire that incorporates 15 measures/items. For the purposes of our study, the following 7 measures were used: (1) assessment of functional ability, through the Juvenile Arthritis Functionality Scale (JAFS)<sup>23</sup>. The JAFS is a 15-item questionnaire in which the ability of the child to perform each task is scored as follows: 0 = without difficulty, 1 = with difficulty, 2 = unable to do. The total score ranges from 0 to 30; (2) assessment of health-related quality of life (HRQOL) through the Paediatric Rheumatology Quality of Life Scale (PRQL)<sup>24</sup>. The PRQL is a 10-item questionnaire that includes 2 subdimensions, each composed of 5 items. The total score ranges from 0 to 30, with higher scores indicating worse HRQOL. A separate score for the physical health and psychosocial health subscales (range 0–15) can be calculated; (3 to 5) rating of the child's well-being, pain intensity, and level of disease activity on a 21-numbered circle visual analog scale (VAS; 0 = best; 10 = worst)<sup>25</sup>; (6) subjective rating of the disease status as remission, continued activity, or flare. To facilitate understanding of disease states by parents and children, remission was defined as "complete absence of symptoms," continued disease activity as "continuing presence of symptoms," and flare as "recurrence of symptoms after a period of complete well-being"; and (7) a question about satisfaction with the present symptom state. The question, "Considering all the ways the illness affects your child, would you be satisfied if his/her condition remained stable/unchanged for the next few months?" was to be answered "yes" or "no." The wording of the question was taken from the definition of the con-

cept of PASS suggested at the Outcome Measures in Rheumatology (OMERACT) 8 meeting<sup>26</sup>.

**Assessment of physician-reported outcomes.** The attending physician rated the overall level of disease activity on a 21-numbered circle VAS (0 = no activity; 10 = maximum activity)<sup>25</sup>, and assessed the count of joints with swelling, tenderness/pain on motion, restricted motion, and active disease<sup>27</sup>. The physician also rated subjectively the current disease status as remission, continued activity, or flare (defined as above). The physician was instructed to base this evaluation on his/her personal opinion about the current disease state and disease course since the previous visit.

**Additional assessments.** The following data were recorded for each patient: sex, onset age, ILAR category, age at visit, and disease duration. Acute-phase reactants included erythrocyte sedimentation rate and C-reactive protein.

**Statistical analyses and validation procedures.** Descriptive statistics were reported as medians and interquartile ranges (IQR) for continuous variables and as absolute frequencies and percentages for categorical variables. Comparison of quantitative data was made through the Mann-Whitney U test. Comparison of categorical variables was made by means of the chi-squared test or Fisher's exact test, as appropriate.

The cutoff value for each outcome measure at which parents and children considered the symptom state as satisfactory (i.e., who answered "yes" to the satisfaction question) was estimated using 2 approaches. In the first, the parent acceptable symptom state in juvenile arthritis (JA-PASS) and the child acceptable symptom state in juvenile arthritis (JA-CASS) were defined as the 75th percentile of the cumulative distribution for each outcome for parents and children, respectively, who considered the symptom state as satisfactory<sup>18,20</sup>. In the second approach, we determined the JA-PASS/JA-CASS cutoffs by plotting receiver-operating characteristic (ROC) curves and identifying the cutoffs that yielded the smallest number of false positives and false negatives<sup>20</sup>.

To investigate the relative effect of covariates on JA-PASS/JA-CASS, a logistic regression analysis was performed, entering explanatory variables (Table 1) that showed significant results in univariate tests and JA-PASS or JA-CASS positivity (i.e., a positive answer to the satisfaction question) as the outcome variable. In the case of 2 or more variables being highly correlated (i.e., redundant), only the most relevant variable was included in the model. Before performing multivariate analysis, continuous variables were converted to binary variables using the cutoffs obtained through the ROC curve analysis. Cases with missing variables were excluded. Using a backward selection procedure, predictor variables that were significantly associated with the outcome were identified. The effect was expressed in terms of OR and 95% CI; statistical significance was tested by means of the likelihood-ratio test. The area under the ROC curve (AUC-ROC) of the best-fitting model was used as an indicator of its predictive ability.

Construct and discriminative validity of the satisfaction question were assessed by comparing the proportion of JA-PASS/JA-CASS-positive patients (i.e., patients who responded "yes" to the satisfaction question) and JA-PASS/JA-CASS-negative patients (i.e., patients who responded "no" to the satisfaction question) who met the criteria for inactive disease<sup>7</sup> or minimal disease activity<sup>12</sup> in JIA, or were judged subjectively as being in remission, continued activity, or disease flare by the parent, the child, or the physician. It was anticipated that for the satisfaction question to demonstrate good construct/discriminative validity there should be relatively more JA-PASS/JA-CASS-positive cases among patients with inactive disease, remission, or minimal disease activity, and relatively more JA-PASS/JA-CASS-negative cases among patients with continued disease activity or flare.

Reliability of the cutoff values of outcome measures that defined the JA-PASS and JA-CASS was determined by evaluating the stability of the cutoffs longitudinally at first, second, and third study visits. Differences in longitudinal cutoffs were interpreted qualitatively.

All statistical tests were 2-sided; a p value  $< 0.05$  was considered statistically significant. The statistical packages used were Statistica (StatSoft

Table 1. Demographic and disease severity characteristics of children with juvenile idiopathic arthritis at first visit according to JA-PASS or JA-CASS. Values are the median (interquartile range) unless otherwise indicated.

Variable	Score Range	N	All Patients, n = 584	JA-PASS+, n = 385	JA-PASS-, n = 199	JA-CASS+, n = 236	JA-CASS-, n = 107
Female, n (%)		584	464 (79.5)	303 (78.7)	161 (80.9)	180 (76.3)	87 (81.3)
Onset age, yrs		584	2.8 (1.7, 5.8)	2.9 (1.8, 5.8)	2.7 (1.7, 6)	4.7 (2.5, 8)	4.5 (1.8, 10.6)
Disease duration, yrs		584	3.6 (1.3, 7.5)	4.1 (1.9, 7.6)	1.8 (0.5, 6.5)	7.1 (4.1, 10.1)	6.6 (3.9, 9.9)
Age at visit, yrs		584	8.8 (4.8, 12.9)	9.2 (5.4, 12.9)	8.1 (3.4, 12.4)	12.1 (9.7, 15.2)	12.8 (10.1, 15.6)
ILAR category, n (%)		584					
Systemic arthritis			43 (7.4)	22 (5.7)	21 (10.6)	18 (7.6)	10 (9.3)
Oligoarthritis persistent			258 (44.2)	168 (43.6)	90 (45.2)	98 (41.5)	41 (38.3)
Oligoarthritis extended			93 (15.9)	66 (17.1)	27 (13.6)	39 (16.5)	19 (17.8)
Polyarthritis RF-negative			132 (22.6)	89 (23.1)	43 (21.6)	49 (20.8)	21 (19.6)
Polyarthritis RF-positive			9 (1.5)	7 (1.8)	2 (1)	5 (2.1)	3 (2.8)
Psoriatic arthritis			13 (2.2)	11 (2.9)	2 (1)	9 (3.8)	1 (0.9)
Enthesitis-related arthritis			12 (2.1)	6 (1.6)	6 (3)	9 (3.8)	3 (2.8)
Undifferentiated arthritis			24 (4.1)	16 (4.2)	8 (4)	9 (3.8)	9 (8.4)
Parent or child well-being VAS score	0–10	569	1.5 (0, 5)	0.5 (0, 2)	5 (3, 6)	0.5 (0, 1)	3 (1, 5)
Parent or child pain VAS score	0–10	561	0.5 (0, 4)	0 (0, 1.5)	5 (2, 6.5)	0 (0, 1)	3.25 (0.5, 6)
Parent or child disease activity VAS score	0–10	561	1 (0, 4.5)	0.5 (0, 1.5)	5 (3, 7)	0 (0, 1)	3.25 (1, 6)
Parent or child JAFS total score	0–30	576	0 (0, 3)	0 (0, 1)	3 (1, 6)	0 (0, 1)	1 (0, 4)
Parent or child PRQL total score	0–30	559	3 (1, 6)	2 (0, 4)	7 (3, 11)	2 (0, 4)	5 (3, 8)
Parent or child PRQL-PhH score	0–15	563	2 (0, 4)	1 (0, 3)	4 (2, 7)	1 (0, 2)	3 (1.75, 5)
Parent or child PRQL-PsH score	0–15	559	1 (0, 3)	1 (0, 2)	2 (1, 4)	1 (0, 2)	1 (1, 3)
Physician global assessment VAS	0–10	478	0.5 (0, 4.5)	0 (0, 4.5)	5 (2.5, 4.5)	0 (0, 4.5)	3.5 (1, 4.5)
No. disease-active joints	0–73	478	1 (0, 2)	0 (0, 1)	3 (1, 5)	0 (0, 1)	2 (1, 4)
No. swollen joints	0–68	478	1 (0, 2)	0 (0, 1)	2 (1, 4)	0 (0, 1)	2 (1, 3)
No. tender joints	0–73	478	1 (0, 2)	0 (0, 1)	2 (1, 5)	0 (0, 1)	2 (1, 4)
No. restricted joints	0–71	478	1 (0, 2)	0 (0, 1)	2 (1, 4)	0 (0, 1)	1 (0, 3.75)
ESR, mm/h	20–140	390	16 (10, 29)	13 (8, 29)	31 (15, 29)	13 (8, 29)	24 (14, 29)
C-reactive protein, mg/dl	< 0.46–infinity*	400	0.3 (0.3, 0.6)	0.3 (0.3, 0.6)	0.6 (0.3, 0.6)	0.3, (0.3, 0.6)	0.3 (0.3, 0.6)

\* All values below 0.46 mg/dl were converted to 0.3 mg/dl. JA-PASS: parent acceptable symptom state in juvenile arthritis; JA-CASS: child acceptable symptom state in juvenile arthritis; ILAR: International League of Associations for Rheumatology; RF: rheumatoid factor; VAS: visual analog scale; JAFS: Juvenile Arthritis Functionality Scale; PRQL: Paediatric Rheumatology Quality of Life Scale; PhH: physical health; PsH: psychosocial health; ESR: erythrocyte sedimentation rate.

Corp., Tulsa, OK, USA) and Stata release 11 (Stata Corp., College Station, TX, USA).

## RESULTS

**Patient characteristics.** The parents of 584 children with JIA completed the JAMAR and responded to the question about satisfaction with illness outcome. The same assessments were performed independently by 343 children aged  $\geq 7$  years. The main demographic and clinical features as well as the values of parent-reported, child-reported, and physician-reported outcome measures and acute-phase reactant levels at study entry are presented in Table 1.

**Assessment of JA-PASS and JA-CASS status.** Of the 584 parents, 385 (65.9%) indicated that they considered their child in JA-PASS. Of the 343 children, 236 (68.8%) indicated that they considered themselves in JA-CASS. The percentage of missing data, that is, the percentage of the whole JAMAR completers (618 parents and 354 children) who did not respond to the question about satisfaction with illness out-

come was 5.5% for JA-PASS and 3.1% for JA-CASS. The characteristics of JA-PASS/JA-CASS-positive and JA-PASS/JA-CASS-negative patients are shown in Table 1. Patients in JA-PASS had longer disease duration and were older than patients not in JA-PASS. There were no differences in the remaining demographic features between JA-PASS/JA-CASS-positive and -negative patients. Patients in JA-PASS or JA-CASS had lower (better) values for all parent/child-reported outcomes, physician-reported outcomes, and acute-phase reactant levels than did patients not in JA-PASS or JA-CASS.

**Effect of covariates on the JA-PASS and JA-CASS.** In stepwise logistic regression analyses (Table 2), being in JA-PASS was independently associated with absence of active joints, better rating of overall well-being, normal physical function, and longer disease duration. Significant contributors to JA-CASS included absence of active joints and better overall well-being and physical health. The AUC-ROC of the model was good ( $> 0.8$ ) for both JA-PASS and JA-CASS. Notably, the pain rating was not included in

Table 2. Best-fitting models obtained through logistic regression procedures with the presence of JA-PASS or JA-CASS status as dependent variables. The area under the receiver-operating characteristic curve of the model was 0.88 for JA-PASS and 0.83 for JA-CASS.

Dependent variables = presence of JA-PASS, n = 446			Dependent variables = presence of JA-CASS, n = 256		
Explanatory Variable	OR (95% CI)	p*	Explanatory Variable	OR (95% CI)	p*
No. disease-active joints = 0	6.6 (3.3–12.9)	< 0.0001	No. active joints = 0	6.0 (2.8–12.7)	< 0.0001
Parent well-being VAS score ≤ 1.5	5.8 (3.2–10.6)	< 0.0001	Child well-being VAS score ≤ 1	3.1 (1.5–6.1)	0.002
JAFS score = 0	2.8 (1.6–4.9)	0.0005	PRQL-PhH score ≤ 1	3.0 (1.4–6.1)	0.003
Disease duration > 1.3 yrs	2.4 (1.3–4.3)	0.004			

\* By likelihood ratio test. JA-PASS: parent acceptable symptom state in juvenile arthritis; JA-CASS: child acceptable symptom state in juvenile arthritis; JAFS: Juvenile Arthritis Functionality Scale; VAS: visual analog scale; PRQL-PhH: Paediatric Rheumatology Quality of Life Scale-Physical Health.

multivariate models because it was highly correlated with the rating of overall well-being.

*Cutoff values of outcome measures for being in JA-PASS or JA-CASS.* The cutoff values of parent-reported, child-reported, and physician-reported outcome measures and acute-phase reactant levels, defined by the 75th percentile of the cumulative distribution and the ROC curve method, that corresponded with a symptom state considered satisfactory by parents or children are presented in Tables 3 and 4. The percentage of false-positive misclassification when applying the 75th percentile threshold and the sensitivity and specificity of ROC curve cutoffs are also reported. Overall, cutoffs were lower for JA-CASS than for JA-PASS. The percentage of patients with scores below the 75th percentile or ROC curve thresholds but still reporting not being in JA-PASS/JA-CASS, that is, the percentage of patients false-positively misclassified as being JA-PASS/JA-CASS-positive<sup>19</sup>, ranged from 10.1% to 24.2% for JA-PASS and from 13.6% to 26.6% for JA-CASS. The variable that provided

the greatest percentage of false-positively misclassified patients for both JA-PASS and JA-CASS was assessment of psychosocial health.

The surprisingly low rate of misclassification yielded by physician global rating is worth mentioning. The best trade-off between sensitivity and specificity was provided by parent-reported, child-reported, and (only for JA-PASS) physician-reported global ratings, whereas joint counts revealed good specificity but low sensitivity, and acute-phase reactant levels showed fair sensitivity but poor specificity. The poor performance of psychosocial health assessment was confirmed by its modest levels of sensitivity and specificity. JA-PASS and JA-CASS thresholds were higher for most variables in patients with systemic arthritis than in those with oligoarthritis and polyarthritis (results not shown).

*Evaluation of construct and discriminative ability of the JA-PASS and JA-CASS.* The proportion of JA-PASS/JA-CASS-positive and JA-PASS/JA-CASS-negative patients who met the criteria for inactive disease<sup>7</sup> or minimal disease

Table 3. JA-PASS cutoff values for parent-reported and physician-reported outcome measures and acute-phase reactant levels as defined by the 75th percentile of the cumulative distribution of each specific measure or ROC curve analysis, percentage of patients with scores below these cutoffs but still reported by their parents not being in JA-PASS (i.e., false positives), and sensitivity and specificity of ROC cutoffs.

Variable and Range	75th Percentile Cutoff	False Positives, n (%)	ROC Cutoff	Sensitivity, %	Specificity, %
Parent well-being VAS score, 0–10	2	40 (12)	1.5	72.5	86.2
Parent pain VAS score, 0–10	1.5	42 (12.6)	2.5	85.3	70.6
Parent disease activity VAS score, 0–10	1.5	31 (10.1)	3	88.1	71.9
Parent JAFS total score, 0–30	1	69 (18.1)	0	70.6	76.9
Parent PRQL total score, 0–30	4	59 (16.6)	4	78.4	67.2
Parent PRQL-PhH score, 0–15	3	78 (19.4)	2	74.7	70.5
Parent PRQL-PsH score, 0–15	2	99 (24.2)	1	67	64.4
PGA VAS, 0–10	2	32 (11.3)	2	77.5	79.1
No. disease-active joints, 0–73	1	51 (17.1)	0	59.7	91.5
No. swollen joints, 0–68	1	62 (19.1)	0	63.7	86.9
No. tender joints, 0–73	1	59 (19)	0	64.9	84.3
No. restricted joints, 0–71	1	75 (23.1)	0	61.8	75.8
ESR, mm/h, 20–140	21	48 (19.4)	25	84.5	55.2
CRP, mg/dl, < 0.46–infinity*	0.3	54 (19.4)	0.3	84.3	59.4

\* All values below 0.46 mg/dl were converted to 0.3 mg/dl. JA-PASS: parent acceptable symptom state in juvenile arthritis; ROC: receiver-operating characteristic; VAS: visual analog scale; JAFS: Juvenile Arthritis Functionality Scale; PRQL: Paediatric Rheumatology Quality of Life Scale; PhH: physical health; PsH: psychosocial health; PGA: physician global assessment; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.

**Table 4.** JA-CASS cutoff values for parent-reported and physician-reported outcome measures and acute-phase reactant levels as defined by the 75th percentile of the cumulative distribution of each specific measure or ROC curve analysis, percentage of patients with scores below these cutoffs but still reported by their parents not being in JA-CASS (i.e., false positives), and sensitivity and specificity of ROC cutoffs.

Variable and Range	75th Percentile Cutoff	False Positives, n (%)	ROC Cutoff	Sensitivity, %	Specificity, %
Child well-being VAS score, 0–10	1	30 (14.5)	1	75.6	72.0
Child pain VAS score, 0–10	1	33 (15.3)	1.5	82.1	66.3
Child disease activity VAS score, 0–10	1	29 (14.4)	0.5	70.7	81.7
Child JAFS total score, 0–30	1	54 (21.9)	0	66.9	65.4
Child PRQL total score, 0–30	4	49 (20.6)	2	60.2	76.6
Child PRQL-PhH score, 0–15	2	42 (17.9)	1	67.4	75.7
Child PRQL-PsH score, 0–15	2	70 (26.6)	0	41.5	75.7
PGA VAS, 0–10	1	23 (13.6)	1.5	64.4	78.5
No. disease-active joints, 0–73	1	30 (16.9)	0	63.1	85.1
No. swollen joints, 0–68	1	36 (18.8)	0	70.1	77.0
No. tender joints, 0–73	1	30 (16.9)	0	67.4	81.1
No. restricted joints, 0–71	1	40 (22.1)	0	58.8	71.6
ESR, mm/h, 20–140	20	32 (19.9)	19	73.8	61.8
CRP, mg/dl, < 0.46–infinity*	0.3	41 (22.2)	0.3	85.2	47.4

\* All values below 0.46 mg/dl were converted to 0.3 mg/dl. JA-CASS: child acceptable symptom state in juvenile arthritis; ROC: receiver-operating characteristic; VAS: visual analog scale; JAFS: Juvenile Arthritis Functionality Scale; PRQL: Paediatric Rheumatology Quality of Life Scale; PhH: physical health; PsH: psychosocial health; PGA: physician global assessment; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.

**Table 5.** Proportions of patients who had inactive disease or minimal disease activity according to established criteria or were judged subjectively as being in remission, continued disease activity, or disease flare by parents, children, and physicians, sorted by JA-PASS and JA-CASS status. Values are the number/total number (%).

Disease Status	N	JA-PASS+, n (%)	JA-PASS–, n (%)	N	JA-CASS+, n (%)	JA-CASS–, n (%)
Inactive disease <sup>7</sup>	124	119 (96.0)	5 (4.0)	79	73 (92.4)	6 (7.6)
Minimal disease activity <sup>12</sup>	223	207 (92.8)	16 (7.2)	147	129 (87.8)	18 (12.2)
Parent or children report	571			332		
Remission	258	249 (96.5)	9 (3.5)	185	171 (92.4)	14 (7.6)
Continued disease activity	171	63 (36.8)	108 (63.2)	71	29 (40.8)	42 (59.2)
Disease flare	142	64 (45.1)	78 (54.9)	76	28 (36.8)	48 (63.2)
Physician report	407			212		
Remission	191	175 (91.6)	16 (8.4)	115	103 (89.6)	12 (10.4)
Continued disease activity	179	90 (50.3)	89 (49.7)	79	41 (51.9)	38 (48.1)
Disease flare	37	15 (40.5)	22 (59.5)	18	4 (22.2)	14 (77.8)

p < 0.001 for all comparisons between PASS-parent and PASS-child-positive and -negative patients. JA-PASS: parent acceptable symptom state in juvenile arthritis; JA-CASS: child acceptable symptom state in juvenile arthritis.

activity<sup>12</sup> in JIA or were judged as being in remission, continued activity, or disease flare by the parent, the child, or the physician is reported in Table 5. As expected, there were relatively more JA-PASS/JA-CASS–positive cases among patients with inactive disease, remission, or minimal disease activity, and relatively more JA-PASS/JA-CASS–negative cases among patients with continued activity or disease flare.

**Evaluation of reliability of the JA-PASS and JA-CASS.** Reliability of cutoffs of outcome measures that defined the JA-PASS and JA-CASS was determined by evaluating their stability over time. This analysis was made by evaluating the JA-PASS or JA-CASS estimates, obtained with the 75th

percentile approach, in 171 children who were reported as being in JA-PASS by their parents in 3 consecutive visits, and in 85 children who reported themselves as being in JA-CASS in 2 consecutive visits. The median (IQR) interval between first and second visit and between second and third visit was 5.8 months (range 3.3–7.3) and 6 months (range 3.6–8), respectively. As shown in Table 6, the cutoffs remained stable throughout visits.

## DISCUSSION

The purpose of our study was to use the question about the satisfaction with illness outcome to define the cutoff values of JIA outcome measures that corresponded with a disease

*Table 6.* JA-PASS and JA-CASS cutoff values for parent-reported, child-reported, and physician-reported outcome measures and acute-phase reactant levels at baseline, second, and third visit in children who were reported as being in JA-PASS by their parents in 3 consecutive visits or reported themselves as being in JA-CASS in 2 consecutive visits (75% percentile approach).

Variable and Range	JA-PASS, n = 171			JA-CASS, n = 85	
	First Visit	Second Visit	Third Visit	First Visit	Second Visit
Parent/child well-being VAS score, 0–10	2	2	1.5	1.2	1
Parent/child pain VAS score, 0–10	1.5	1	1	1	1
Parent/child disease activity VAS score, 0–10	2	1.5	1	1	1
Parent/child JAFS total score, 0–30	1	0	0	1	1
Parent/child PRQL total score, 0–30	4	3	3	3	3
Parent/child PRQL-PhH score, 0–15	2.5	2	2	2	1
Parent/child PRQL-PsH score, 0–15	2	2	2	2	1
Physician global assessment VAS, 0–10	1.1	1.5	1	1	1
No. active joints, 0–73	1	2	1	1	1
No. swollen joints, 0–68	1	1	1	1	1
No. tender joints, 0–73	1	1	1	2	2
No. restricted joints, 0–71	1	2	1	1	1
ESR, mm/h, 20–140	22	19	23	21	19
CRP, mg/dl, < 0.46–infinity*	0.3	0.3	0.3	0.3	0.3

\* All values below 0.46 mg/dl were converted to 0.3 mg/dl. JA-PASS: parent acceptable symptom state in juvenile arthritis; JA-CASS: child acceptable symptom state in juvenile arthritis; VAS: visual analog scale; JAFS: Juvenile Arthritis Functionality Scale; PRQL: Paediatric Rheumatology Quality of Life Scale; PhH: physical health; PsH: psychosocial health; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.

state deemed acceptable by parents and children. The validity of the satisfaction question was tested by assessing its discriminative and construct validity. The reliability of cutoff values of outcome measures was examined by evaluating their stability over time.

In a cross-sectional population of patients with JIA seen in the context of standard clinical care, the majority of parents (65.9%) and children (68.9%) declared being satisfied if the child's current condition remained stable/unchanged for the next few months. Multivariate analyses revealed that the major contributor to being in both JA-PASS and JA-CASS was the absence of active joints. This underscores the importance of joint symptoms in driving parents' and children's judgment regarding the acceptability of the disease status. Other disease-related covariates independently associated with both JA-PASS and JA-CASS were overall well-being and physical health status. That the independent contributors were similar among parents and children adds to the clinical relevance and reliability of the JA-PASS/JA-CASS concept. Notably, pain rating was not included in multivariate models because it was highly correlated with assessment of well-being. The association between being in JA-PASS and a longer disease duration may reflect parents' adaptation to the disease burden over time or a greater likelihood of achievement of a satisfactory disease control in the later stages of the illness.

We estimated cutoff values for parent-reported, child-reported, and physician-reported outcome measures, and acute-phase reactant levels that defined the JA-PASS and JA-CASS, using both the 75th percentile method and the

ROC curve analysis. Overall, JA-PASS and JA-CASS cutoffs were similar when obtained by either method, which ensures their robustness across statistical approaches. Threshold levels for JA-CASS were lower than those for JA-PASS, suggesting that children may require a more stringent disease control to feel satisfied. JA-PASS and JA-CASS cutoffs for parent/child global assessment of well-being or disease activity and physician's global assessment of disease activity were similar. This observation may reflect a similar perspective and expectations of doctors, parents, and children regarding the achievement of satisfactory disease activity and health status. Notably, parent, child, and physician global ratings were the variables less affected by false-positive misclassification and revealed the best tradeoff between sensitivity and specificity. That the assessment of psychosocial health yielded the highest frequency of misclassification and had the poorest performances in terms of sensitivity and specificity is not surprising, because this measure is affected by many factors unrelated to the disease<sup>28,29</sup>. An alternative hypothesis is that parents and children tend to relate the burden of chronic arthritis to physical rather than psychosocial impairment. Neither the JA-PASS nor the JA-CASS cutoffs fit the criteria for inactive disease<sup>7</sup>, whereas both fell within the thresholds of MDA<sup>12</sup>. This is due to the greater stringency of the former criteria, which require the formal absence of clinical and laboratory evidence of disease activity. Threshold levels for both JA-PASS and JA-CASS were higher in systemic arthritis than in the other ILAR categories, reflecting the greater burden of the systemic JIA subset.

Construct and discriminative validity of the satisfaction question were established by showing that there were relatively more JA-PASS/JA-CASS-positive cases among patients with inactive disease, remission, or minimal disease activity, and relatively more JA-PASS/JA-CASS-negative cases among patients with continued activity or disease flare. Evidence of reliability of the cutoff values of outcome measures that defined the JA-PASS and JA-CASS was provided by the finding that cutoffs remained stable over time.

Several potential caveats should be taken into account in interpreting our study. The wording of the question about satisfaction with the symptom state was taken from wording suggested by the OMERACT group, with no previous validation in pediatric patients. We recognize that potential differences in the assessment of disease states of adults with chronic arthritis and the complex developmental situation of children with JIA and their parents were not considered. Further, the effects of age-related or development-related differences in the ability of children to understand the states of diseases were not taken into account. Because the concept of acceptable symptom state is new in pediatric rheumatology, the specific wording of the question and the timeframe to evaluate the present health state for the next several months should be explored further. It should also be investigated whether criteria other than the satisfaction question could be more suitable to define the acceptable symptom state in children with chronic arthritis. The study sample included few patients with psoriatic arthritis and enthesitis-related arthritis. Thus, our findings may be of limited value for children with these JIA subtypes. We did not examine the role of coping, self-efficacy, anxiety, depression, and treatment expectations. Because perceptions of the larger beneficial effects of treatment will influence parent and patient concepts of acceptable symptom state, it is possible that estimates may differ in patients who have experienced the benefits of anti-tumor necrosis factor therapies. This evaluation could not be performed, however, owing to the insufficient number of observations.

Our study showed that the JA-PASS/JA-CASS is a relevant concept for children with JIA and their parents and constitutes a valid outcome measure that is potentially applicable in routine practice as well as in clinical trials. Application of JA-PASS/JA-CASS may provide practicing pediatric rheumatologists with a feasible and valuable instrument that may help improve the quality of clinical care.

## REFERENCES

- Ravelli A, Martini A. Juvenile idiopathic arthritis. *Lancet* 2007;369:767-78.
- Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. *JAMA* 2005;294:1671-84.
- Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: Treatment of juvenile idiopathic arthritis. *Arthritis Res Ther* 2009;11:216.
- Martini A, Lovell DJ. Juvenile idiopathic arthritis: State of the art and future perspectives. *Ann Rheum Dis* 2010;69:1260-3.
- Scott C, Meiorin S, Filocamo G, Lanni S, Valle M, Martinoli C, et al. A reappraisal of intra-articular corticosteroid therapy in juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2010;28:774-81.
- Ruperto N, Giannini EH, Pistorio A, Brunner HI, Martini A, Lovell DJ. Is it time to move to active comparator trials in juvenile idiopathic arthritis? A review of current study designs. *Arthritis Rheum* 2010;62:3131-9.
- Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. *J Rheumatol* 2004;31:2290-4.
- Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. *Arthritis Rheum* 2005;52:3554-62.
- Ravelli A, Martini A. Remission in juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2006;24 (Suppl 43):S105-10.
- Wells G, Boers M, Shea B, Anderson J, Felson D, Johnson K, et al. MCID/low disease activity state workshop: Low disease activity state in rheumatoid arthritis. *J Rheumatol* 2003;30:1110-1.
- Tubach F, Wells GA, Ravaud P, Dougados M. Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: Methodological issues. *J Rheumatol* 2005;32:2025-9.
- Magni-Manzoni S, Ruperto N, Pistorio A, Sala E, Solari N, Palmisani E, et al. Development and validation of a preliminary definition of minimal disease activity in juvenile idiopathic arthritis. *Arthritis Rheum* 2008;59:1120-7.
- Dougados M. It's good to feel better but it's better to feel good. *J Rheumatol* 2005;32:1-2.
- Ravelli A, Viola S, Migliavacca D, Pistorio A, Ruperto N, Martini A. Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis. *Rheumatology* 2001;40:914-9.
- Garcia-Munitis P, Bandeira M, Pistorio A, Magni-Manzoni S, Ruperto N, Schivo A, et al. Level of agreement between children, parents, and physicians in rating pain intensity in juvenile idiopathic arthritis. *Arthritis Rheum* 2006;55:177-83.
- Sztajn bok F, Coronel-Martinez DL, Diaz-Maldonado A, Novarini C, Pistorio A, Viola S, et al. Discordance between physician's and parent's global assessments in juvenile idiopathic arthritis. *Rheumatology* 2007;46:141-5.
- Consolaro A, Vitale R, Pistorio A, Lattanzi B, Ruperto N, Malattia C, et al. Physicians' and parents' ratings of inactive disease are frequently discordant in juvenile idiopathic arthritis. *J Rheumatol* 2007;34:1773-6.
- Kvien TK, Heiberg T, Hagen KB. Minimal clinically important improvement/difference (MCII/MCID) and patients acceptable symptom state (PASS): What do these concepts mean? *Ann Rheum Dis* 2007;66 (Suppl III):iii40-1.
- Maksymowych WP, Richardson R, Mallon C, van der Heijde D, Boonen A. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. *Arthritis Rheum* 2007;57:133-9.
- Heiberg T, Kvien TK, Mowinckel P, Aletaha D, Smolen JS, Hagen KB. Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. *Ann Rheum Dis* 2008;67:967-71.
- Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. *J Rheumatol* 2004;31:390-2.
- Filocamo G, Consolaro A, Schiappapietra B, Dalprà S, Lattanzi B, Magni-Manzoni S, et al. A new approach to clinical care of juvenile idiopathic arthritis: The Juvenile Arthritis Multidimensional

- Assessment Report. *J Rheumatol* 2011;38:938-53.
23. Filocamo G, Sztajn bok F, Cespedes-Cruz A, Magni-Manzoni S, Pistorio A, Viola S, et al. Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis. *Arthritis Rheum* 2007;57:913-20.
  24. Filocamo G, Schiappapietra B, Bertamino M, Pistorio A, Ruperto N, Magni-Manzoni S, et al. A new short and simple health-related quality of life measurement for paediatric rheumatic diseases: Initial validation in juvenile idiopathic arthritis. *Rheumatology* 2010;49:1272-80.
  25. Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lattanzi B, et al. Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. *J Rheumatol* 2010;37:1534-41.
  26. Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Felson DT, et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. *J Rheumatol* 2007;34:1188-93.
  27. Ravelli A, Viola S, Ruperto N, Corsi B, Ballardini G, Martini A. Correlation between conventional disease activity measures in juvenile chronic arthritis. *Ann Rheum Dis* 1997;56:197-200.
  28. Brunner HI, Giannini EH. Health-related quality of life in children with rheumatic diseases. *Curr Opin Rheumatol* 2003;15:602-12.
  29. Duffy CM. Measurement of health status, functional status, and quality of life in children with juvenile idiopathic arthritis: Clinical science for the pediatrician. *Pediatr Clin North Am* 2005;52:359-72.